Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The order is placed and delivered in 2 days
Strive offers BPC-157 which has been thoroughly tested by an independent third-party lab, to provide every measure to ensure that customers receive only the highest quality product possible
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
The lightweight and fast-absorbing formula purifies and brightens
US$ 26.45
US$ 24.28
US$ 25.16
